Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lyophilised Oxalobacter formigenes - OxThera AB

Drug Profile

Lyophilised Oxalobacter formigenes - OxThera AB

Alternative Names: IxOC 3; Lyophylised Oxalobacter formigenes; OC 3; OC5; Oxabact; Oxabact OC5 - Oxalobacter formigenes HC-1; Oxalobacter

Latest Information Update: 22 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ixion Biotechnology
  • Developer OxThera
  • Class Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria; Short bowel syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Primary hyperoxaluria
  • No development reported Short bowel syndrome

Most Recent Events

  • 22 Feb 2023 Phase III clinical development is still ongoing in Primary hyperoxaluria (In children, In adolescents, In adults, In the elderly) in United Kingdom, USA, Belgium, Tunisia and France (PO) (OxThera AB pipeline, February 2023)
  • 03 Sep 2021 OxThera terminates a phase III ePHex-OLE extension study in Primary hyperoxaluria (In adolescents, In children, In the elderly, In adults) in Belgium, Germany, Spain and United Kingdom as the parent trial OC5-DB-02 did not achieve primary endpoint (PO) (NCT03938272)
  • 11 Jun 2021 Efficacy and adverse events data from a phase III OC5-DB-02 trial in Primary hyperoxaluria released by OxThera
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top